FDA accepts Merck’s pneumococcal vaccine BLA for priority review

The US Food and Drug Administration (FDA) has accepted the new biologics licence application (BLA) for MSD’s investigational 21-valent pneumococcal conjugate vaccine, V116, for priority review.